Filtered By:
Condition: Heart Failure
Drug: Pradaxa
Management: National Institute for Health and Clinical Excelle
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
NICE issues final guidance supporting the use of apixaban for prevention of stroke and systemic embolism in non-valvular atrial fibrillation (TA 275)
Source: NICE
Area: Evidence > Guidelines
NICE has issued final guidance (TA 275) supporting the use of apixaban as an option for preventing stroke and systemic embolism within its marketing authorisation, that is, in people with nonvalvular atrial fibrillation with 1 or more risk factors such as:
. prior stroke or transient ischaemic attack
. age 75 years or older
. hypertension
. diabetes mellitus
. symptomatic heart failure.
NICE notes that the decision about whether to start treatment with apixaban should be made after an informed discussion between the clinici...
Source: NeLM - Cardiovascular Medicine - February 27, 2013 Category: Cardiology Source Type: news
